Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
about
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon betaRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisRisks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisNeutralizing antibodies against interferon-BetaClinical testing for neutralizing antibodies to interferon-β in multiple sclerosisThe challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.Detection of anti-cytokine antibodies and their clinical relevance.Applications of cell-based bioassays measuring the induced expression of endogenous genes.Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.BAb and MxA as functional biomarkers in routine clinical laboratories for the determination of anti-IFN-beta antibodies and their bioactivity levels in multiple sclerosis patients.Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b
P2860
Q26864418-9548E32F-9856-4386-8A09-6D20F5E668C2Q28087414-9EAF9EF7-93B6-4A68-9FD8-B5F51CAE4EDBQ33802186-50B49FE4-FC15-4324-A8ED-34092F4FD83AQ34409082-E0FB3C10-5B69-417D-BF6F-BA3606D76480Q38070677-C2C02BA7-858A-466A-9DBA-91F08029D277Q38177871-7CF99423-53FB-494A-B0ED-5D7DF71E1499Q38202541-3B535CA3-2595-4165-99ED-E04F901A6E9CQ38217701-9398AF31-33C3-4252-A50E-40A69B820F02Q38232126-22366034-140C-44BF-A761-64D03E920710Q39522086-D25CFCB0-18E8-4790-B073-8F5DAED85673Q43637145-B45640F4-8722-4518-A630-D608D8F1AD94Q43997002-C0ACDED1-8459-49E0-9200-FC9E19AE757BQ46231531-7EB8F764-AEA6-4DCD-B2F0-24E3D61B8A56Q48370561-EFB3BDD3-8A03-4EB7-85A1-AB74C954D807Q57085803-D92749C7-8A2A-4A46-8016-D221B75DF0C7
P2860
Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Measuring and management of an ...... jects with multiple sclerosis.
@en
type
label
Measuring and management of an ...... jects with multiple sclerosis.
@en
prefLabel
Measuring and management of an ...... jects with multiple sclerosis.
@en
P2860
P356
P1476
Measuring and management of an ...... jects with multiple sclerosis.
@en
P2093
Gavin Giovannoni
Rachel A Farrell
P2860
P304
P356
10.1177/1352458506073522
P577
2007-02-16T00:00:00Z